Fortis Healthcare Limited has provided a material litigation update to stock exchanges regarding ongoing proceedings in the Tokyo District Court. The healthcare company disclosed developments in a case involving its promoter shareholder Northern TK Venture Pte Ltd (NTK) against Daiichi Sankyo Company Limited.

Court Proceedings Concluded

The Tokyo District Court has completed both preparatory and oral proceedings in the litigation case filed by Northern TK Venture against Daiichi Sankyo Company Limited. The court proceedings reached this milestone on April 28, 2026, marking a significant development in the ongoing legal matter.

Regulatory Compliance and Disclosure

Fortis Healthcare made this disclosure under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. The announcement references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, demonstrating compliance with regulatory requirements for material event disclosures.

This represents the latest in a series of updates the company has provided to exchanges, with previous announcements dating from November 14, 2023 through February 19, 2026. The systematic disclosure pattern reflects the company's commitment to keeping stakeholders informed about material developments.

IHH Healthcare Connection

The disclosure includes an announcement from IHH Healthcare Berhad, made on April 28, 2026, on both the Malaysian Stock Exchange (Bursa Malaysia) and SGX Stock Exchange. IHH Healthcare's involvement stems from the complex corporate structure involving Northern TK Venture as an indirect wholly-owned subsidiary.

The litigation relates to previous transactions including:

• Subscription of 235,294,117 new equity shares in Fortis Healthcare
• Mandatory open offer for acquisition of up to 197,025,660 Fortis shares
• Related open offer for Malar Hospitals Limited shares

Next Steps and Timeline

With court proceedings now concluded, attention turns to the scheduled judgment announcement on September 10, 2026. Fortis Healthcare has committed to providing further updates in case of any material developments regarding this matter.

The company maintains its disclosure obligations under SEBI regulations, ensuring stakeholders receive timely information about significant legal proceedings that may impact the organization. The structured approach to these announcements demonstrates adherence to corporate governance standards and regulatory compliance requirements.

Fortis Healthcare Limited's Nomination & Remuneration Committee has approved a significant employee stock option grant under its Employee Stock Option Scheme 2026. The committee meeting, held on April 23, 2026, sanctioned the allocation of substantial equity-based compensation to eligible employees as part of the company's talent retention and incentive strategy.

Stock Option Grant Details

The committee approved the grant of 1,32,05,200 employee stock options to eligible employees under the Fortis Healthcare Limited Employee Stock Option Scheme 2026. Each option carries the right to acquire one fully paid-up equity share with a face value of ₹10.

Vesting and Exercise Framework

The stock options operate under a structured timeline designed to align employee interests with long-term company performance. The vesting schedule spans a maximum period of 3 years from the grant date, with specific conditions as determined by the Nomination & Remuneration Committee.

Regulatory Compliance and Scheme Structure

The Employee Stock Option Scheme 2026 operates in full compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The exercise price of ₹923.10 per option was determined based on the closing price on the recognized stock exchange with higher trading volume as of April 22, 2026.

Key features of the scheme include:

• Vesting subject to conditions approved by the Nomination & Remuneration Committee
• Exercise window commencing from vesting date
• Maximum exercise period of 4 years from each vesting milestone
• Compliance with current SEBI regulations for employee benefit schemes

Corporate Governance and Documentation

The grant follows the company's previous intimation dated February 13, 2026, and adheres to disclosure requirements under Regulation 30 of SEBI Listing Regulations. The complete scheme documentation has been made available on the company's website at www.fortishealthcare.com , ensuring transparency for stakeholders.

The approval represents a continuation of Fortis Healthcare's employee engagement strategy, utilizing equity-based compensation to attract and retain talent in the competitive healthcare sector. The substantial option grant reflects the company's commitment to aligning employee interests with shareholder value creation through long-term equity participation.